REYON Pharmaceutical Co., Ltd. (102460.KS)
KRW 13020.0
(-2.18%)
KRW 13020.0
(-2.18%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 151.07 Billion KRW | -1.93% |
| 2022 | 154.03 Billion KRW | 7.87% |
| 2021 | 142.8 Billion KRW | 9.82% |
| 2020 | 130.03 Billion KRW | -1.16% |
| 2019 | 131.55 Billion KRW | 6.97% |
| 2018 | 122.99 Billion KRW | -2.58% |
| 2017 | 126.25 Billion KRW | 3.62% |
| 2016 | 121.84 Billion KRW | 6.41% |
| 2015 | 114.5 Billion KRW | 2.14% |
| 2014 | 112.11 Billion KRW | 2.2% |
| 2013 | 109.69 Billion KRW | -4.06% |
| 2012 | 114.33 Billion KRW | -8.05% |
| 2011 | 124.35 Billion KRW | 2.92% |
| 2010 | 120.82 Billion KRW | 26.94% |
| 2009 | 95.18 Billion KRW | 30.51% |
| 2008 | 72.93 Billion KRW | 30.46% |
| 2007 | 55.9 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 37.01 Billion KRW | -4.73% |
| 2024 Q2 | 35.68 Billion KRW | -3.6% |
| 2023 Q4 | 38.85 Billion KRW | 3.77% |
| 2023 Q2 | 37.74 Billion KRW | 1.93% |
| 2023 Q3 | 37.44 Billion KRW | -0.8% |
| 2023 FY | 151.07 Billion KRW | -1.93% |
| 2023 Q1 | 37.03 Billion KRW | -3.48% |
| 2022 Q4 | 38.36 Billion KRW | -1.38% |
| 2022 Q3 | 38.9 Billion KRW | -1.79% |
| 2022 Q1 | 37.16 Billion KRW | 0.78% |
| 2022 FY | 154.03 Billion KRW | 7.87% |
| 2022 Q2 | 39.6 Billion KRW | 6.58% |
| 2021 Q3 | 36.58 Billion KRW | 2.49% |
| 2021 Q1 | 33.63 Billion KRW | 0.44% |
| 2021 FY | 142.8 Billion KRW | 9.82% |
| 2021 Q2 | 35.7 Billion KRW | 6.14% |
| 2021 Q4 | 36.87 Billion KRW | 0.78% |
| 2020 Q3 | 33.06 Billion KRW | 6.29% |
| 2020 Q2 | 31.11 Billion KRW | -3.88% |
| 2020 Q1 | 32.36 Billion KRW | -2.49% |
| 2020 FY | 130.03 Billion KRW | -1.16% |
| 2020 Q4 | 33.48 Billion KRW | 1.27% |
| 2019 Q2 | 33 Billion KRW | 2.06% |
| 2019 Q4 | 33.19 Billion KRW | 0.54% |
| 2019 FY | 131.55 Billion KRW | 6.97% |
| 2019 Q1 | 32.34 Billion KRW | 8.16% |
| 2019 Q3 | 33.01 Billion KRW | 0.02% |
| 2018 Q3 | 30.71 Billion KRW | -1.69% |
| 2018 FY | 122.99 Billion KRW | -2.58% |
| 2018 Q4 | 29.9 Billion KRW | -2.63% |
| 2018 Q2 | 31.23 Billion KRW | 0.31% |
| 2018 Q1 | 31.14 Billion KRW | 4.64% |
| 2017 FY | 126.25 Billion KRW | 3.62% |
| 2017 Q4 | 29.76 Billion KRW | -6.4% |
| 2017 Q3 | 31.79 Billion KRW | 1.1% |
| 2017 Q2 | 31.45 Billion KRW | -5.39% |
| 2017 Q1 | 33.24 Billion KRW | 9.88% |
| 2016 Q3 | 31.05 Billion KRW | 2.82% |
| 2016 FY | 121.84 Billion KRW | 6.41% |
| 2016 Q4 | 30.25 Billion KRW | -2.57% |
| 2016 Q2 | 30.2 Billion KRW | -0.45% |
| 2016 Q1 | 30.33 Billion KRW | -4.3% |
| 2015 Q3 | 27.78 Billion KRW | 0.08% |
| 2015 Q4 | 31.7 Billion KRW | 14.1% |
| 2015 Q2 | 27.76 Billion KRW | 1.85% |
| 2015 Q1 | 27.25 Billion KRW | -1.77% |
| 2015 FY | 114.5 Billion KRW | 2.14% |
| 2014 Q4 | 27.74 Billion KRW | 1.95% |
| 2014 Q2 | 28.16 Billion KRW | -2.79% |
| 2014 Q1 | 28.97 Billion KRW | 1.82% |
| 2014 FY | 112.11 Billion KRW | 2.2% |
| 2014 Q3 | 27.21 Billion KRW | -3.38% |
| 2013 Q1 | 25.74 Billion KRW | -10.7% |
| 2013 Q2 | 28.49 Billion KRW | 10.69% |
| 2013 Q4 | 28.45 Billion KRW | 5.39% |
| 2013 Q3 | 27 Billion KRW | -5.23% |
| 2013 FY | 109.69 Billion KRW | -4.06% |
| 2012 FY | 114.33 Billion KRW | -8.05% |
| 2012 Q4 | 28.82 Billion KRW | -4.18% |
| 2012 Q3 | 30.08 Billion KRW | -0.75% |
| 2012 Q2 | 30.31 Billion KRW | 20.7% |
| 2012 Q1 | 25.11 Billion KRW | -21.66% |
| 2011 Q2 | 28.86 Billion KRW | -7.07% |
| 2011 Q1 | 31.06 Billion KRW | -3.14% |
| 2011 Q3 | 32.36 Billion KRW | 12.1% |
| 2011 Q4 | 32.05 Billion KRW | -0.95% |
| 2011 FY | 124.35 Billion KRW | 2.92% |
| 2010 Q3 | 31.18 Billion KRW | 6.72% |
| 2010 FY | 120.82 Billion KRW | 26.94% |
| 2010 Q2 | 29.22 Billion KRW | 0.0% |
| 2010 Q4 | 32.07 Billion KRW | 2.84% |
| 2009 FY | 95.18 Billion KRW | 30.51% |
| 2008 FY | 72.93 Billion KRW | 30.46% |
| 2007 FY | 55.9 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -10.102% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 86.655% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 76.338% |
| HANDOK Inc. | 522.74 Billion KRW | 71.1% |
| Kukje Pharma Co., Ltd. | 135.37 Billion KRW | -11.596% |
| Yuhan Corporation | 1858.98 Billion KRW | 91.873% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 77.248% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -190.773% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 89.867% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -11.979% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 59.229% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -70.522% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | 10.908% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | 32.695% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -10.102% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -93.549% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -72.922% |
| JW Holdings Corporation | 928.07 Billion KRW | 83.722% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 74.853% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 90.951% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 79.818% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 24.551% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | 16.426% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | 23.059% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 79.203% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | -10.102% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 90.025% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 89.016% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 79.818% |
| Yuhan Corporation | 1858.98 Billion KRW | 91.873% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 80.99% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | 35.688% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 74.591% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 79.818% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 48.286% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 45.842% |
| CKD Bio Corp. | 160.35 Billion KRW | 5.788% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 71.331% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 58.165% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | 34.429% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 24.551% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 82.829% |
| Boryung Corporation | 859.62 Billion KRW | 82.426% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -19.966% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 59.229% |
| JW Lifescience Corporation | 206.86 Billion KRW | 26.97% |